Skip to main content

Advertisement

Table 4 Pathological characteristics and analytical performances of each method

From: Comparative evaluation of the new FDA approved THxID™-BRAF test with high resolution melting and sanger sequencing

  WT V600 mutation Invalid result
Specimen characteristics HRM Sanger sequencing THxID™-BRAF test HRM Sanger sequencing THxID™-BRAF test HRM Sanger sequencing THxID™-BRAF test
Tumor percentage          
  Samples <80% 12 10 11 1 1 2 0 2 0
  Samples ≥80% 57 52 55 41 45 44 0 3 1
Melanin rate          
  Sample 0 62 56 59 40 45 45 0 4 1
  Sample + (>20%) 4 3 4 1 1 1 0 1 0
  Sample ++ (20 to 50%) 2 2 2 0 0 0 0 0 0
  Sample +++ (≤50%) 1 1 1 0 0 0 0 0 0
Tumor necrosis          
  Sample 0 55 49 53 34 38 39 0 5 0
  Sample + (<10%) 10 9 9 5 6 5 0 0 1
  Sample ++ to +++ (≥10%) 4 4 4 2 2 2 0 0 0